Literature DB >> 21115800

In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008.

Jeannette Ouyang-Latimer1, Syed Jafri, Audrey VanTassel, Zhi-Dong Jiang, Kaur Gurleen, Savio Rodriguez, Ranjan K Nandy, Thandavaryan Ramamurthy, Santanu Chatterjee, Robin McKenzie, Robert Steffen, Herbert L DuPont.   

Abstract

The incidence rates of travelers' diarrhea (TD) have remained high for the last 50 years. More recently, there have been increasing recommendations for self-initiated therapy and use of prophylactic drugs for TD. We last examined the in vitro susceptibilities of commonly used antibiotics against TD pathogens in 1997. We now examine 456 enteropathogens isolated from adult travelers to Mexico, India, and Guatemala with diarrhea acquired between 2006 and 2008 to determine changes in susceptibility against 10 different antimicrobials by the agar dilution method. Traditional antibiotics, such as ampicillin, trimethoprim-sulfamethoxazole, and doxycycline, continue to show high levels of resistance. Current first-line antibiotic agents, including fluoroquinolones and azithromycin, showed significantly higher MICs than in our earlier study, and MIC(90) levels were above the Clinical and Laboratory Standards Institute cutoffs for resistance. There were significant geographical differences in resistance patterns when Central America was compared with India. Entertoxigenic Escherichia coli (ETEC) isolates showed increased resistance to ciprofloxacin (P = 0.023) and levofloxacin (P = 0.0078) in India compared with Central America. Enteroaggregative E. coli (EAEC) isolates from Central America showed increased resistance to nearly all of the antibiotics tested. Compared to MICs of isolates 10 years prior, there were 4- to 10-fold increases in MIC(90) values for ceftriaxone, ciprofloxacin, levofloxacin, and azithromycin for both ETEC and EAEC. There were no significant changes in rifaximin MICs. Rising MICs over time imply the need for continuous surveillance of susceptibility patterns worldwide and geographically specific recommendations in TD therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115800      PMCID: PMC3028774          DOI: 10.1128/AAC.00739-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  Traveler's diarrhea.

Authors:  Anna C Casburn-Jones; Michael J G Farthing
Journal:  J Gastroenterol Hepatol       Date:  2004-06       Impact factor: 4.029

2.  Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers.

Authors:  R D Cofsky; L duBouchet; S H Landesman
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

3.  Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial.

Authors:  H L DuPont; Z D Jiang; C D Ericsson; J A Adachi; J J Mathewson; M W DuPont; E Palazzini; L M Riopel; D Ashley; F Martinez-Sandoval
Journal:  Clin Infect Dis       Date:  2001-10-23       Impact factor: 9.079

4.  In vitro activity and fecal concentration of rifaximin after oral administration.

Authors:  Z D Jiang; S Ke; E Palazzini; L Riopel; H Dupont
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

5.  In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions.

Authors:  H Gomi; Z D Jiang; J A Adachi; D Ashley; B Lowe; M P Verenkar; R Steffen; H L DuPont
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

6.  Prognosis in post-infective irritable bowel syndrome: a six year follow up study.

Authors:  K R Neal; L Barker; R C Spiller
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

7.  Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico.

Authors:  Pablo C Okhuysen; Zhi Dong Jiang; Lily Carlin; Charles Forbes; Herbert L DuPont
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

8.  Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy.

Authors:  Rosa M Infante; Charles D Ericsson; Zhi-Dong Jiang; Shi Ke; Robert Steffen; Lise Riopel; David A Sack; Herbert L DuPont
Journal:  Clin Gastroenterol Hepatol       Date:  2004-02       Impact factor: 11.382

9.  A newly recognized cause of travelers' diarrhea: enteroadherent Escherichia coli.

Authors:  J J Mathewson; P C Johnson; H L DuPont; D R Morgan; S A Thornton; L V Wood; C D Ericsson
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

10.  Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter species.

Authors:  Zhi-Dong Jiang; Herbert L Dupont; Eric L Brown; Ranjan K Nandy; Thandavaryan Ramamurthy; Anuradha Sinha; Santanu Ghosh; Sucharita Guin; Kaur Gurleen; Savio Rodrigues; Jacklyn J Chen; Robin McKenzie; Robert Steffen
Journal:  J Clin Microbiol       Date:  2010-01-27       Impact factor: 5.948

View more
  22 in total

1.  Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control.

Authors:  Jessica C Seidman; Christian L Coles; Ellen K Silbergeld; Joshua Levens; Harran Mkocha; Lashaunda B Johnson; Beatriz Muñoz; Sheila K West
Journal:  Int J Epidemiol       Date:  2014-03-21       Impact factor: 7.196

Review 2.  Advances in the treatment of travelers' diarrhea.

Authors:  Mercedes Paredes-Paredes; Jose Flores-Figueroa; Herbert L Dupont
Journal:  Curr Gastroenterol Rep       Date:  2011-10

Review 3.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

4.  ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults.

Authors:  Mark S Riddle; Herbert L DuPont; Bradley A Connor
Journal:  Am J Gastroenterol       Date:  2016-04-12       Impact factor: 10.864

Review 5.  Use of rifaximin in gastrointestinal and liver diseases.

Authors:  Rani H Shayto; Rachel Abou Mrad; Ala I Sharara
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

6.  Antibiotic Therapy for Acute Watery Diarrhea and Dysentery.

Authors:  David R Tribble
Journal:  Mil Med       Date:  2017-09       Impact factor: 1.437

Review 7.  Clinical implications of enteroadherent Escherichia coli.

Authors:  Margarita M P Arenas-Hernández; Ygnacio Martínez-Laguna; Alfredo G Torres
Journal:  Curr Gastroenterol Rep       Date:  2012-10

Review 8.  Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.

Authors:  Mark S Riddle; Bradley A Connor; Nicholas J Beeching; Herbert L DuPont; Davidson H Hamer; Phyllis Kozarsky; Michael Libman; Robert Steffen; David Taylor; David R Tribble; Jordi Vila; Philipp Zanger; Charles D Ericsson
Journal:  J Travel Med       Date:  2017-04-01       Impact factor: 8.490

Review 9.  Resistant pathogens as causes of traveller's diarrhea globally and impact(s) on treatment failure and recommendations.

Authors:  David R Tribble
Journal:  J Travel Med       Date:  2017-04-01       Impact factor: 8.490

10.  Preclinical Characterization of Immunogenicity and Efficacy against Diarrhea from MecVax, a Multivalent Enterotoxigenic E. coli Vaccine Candidate.

Authors:  Hyesuk Seo; Carolina Garcia; Xiaosai Ruan; Qiangde Duan; David A Sack; Weiping Zhang
Journal:  Infect Immun       Date:  2021-06-16       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.